NHS Approves Two Blood Cancer Treatments for 200 Patients

Starting this week, around 200 patients each year across England will gain access to two newly approved blood cancer treatments that could transform their chances of survival.

NHS England has greenlit dabrafenib for patients with rare histiocytic neoplasms and a combination therapy for young people with hard-to-treat Hodgkin lymphoma. Both treatments represent major steps forward for diseases that previously left families with limited choices.

Dabrafenib offers something particularly groundbreaking for patients with histiocytic neoplasms. These rare blood cancers, driven by specific genetic mutations, can be deadly without effective treatment. One in ten children with high-risk forms die within a year of diagnosis, while seven in ten adults don't survive five years.

The new tablet works by blocking proteins that fuel cancer cell growth, slowing or stopping the disease's progression. Perhaps most importantly, patients can take it at home rather than spending weeks in hospital receiving intensive treatments.

For children and young people battling Hodgkin lymphoma that has returned or resisted initial treatment, the second approval brings new possibilities. The disease affects about 1,800 people in England annually, with up to 30% experiencing relapse or treatment failure.

The combination of brentuximab vedotin and bendamustine works like a targeted missile. It attaches to proteins on cancer cell surfaces and delivers cancer-killing medicine directly into those cells, sparing healthy tissue.

The Ripple Effect

These approvals signal a broader shift in how medicine fights rare cancers. Scientists now understand the genetic changes driving these diseases well enough to design treatments that match each patient's unique genetic profile.

The result goes beyond better survival rates. Targeted therapies typically cause fewer side effects than conventional chemotherapy, meaning patients can maintain more of their normal lives during treatment. Kids can stay in school. Adults can work. Families can focus on living, not just surviving.

The approvals also support the NHS's ambitious 10-Year Cancer Plan, which aims to expand access to personalized therapies for difficult-to-treat diseases. Earlier this year, the health service made similar moves with prostate cancer treatments, showing a clear commitment to bringing cutting-edge science to everyday patients.

For the 200 families who will benefit each year, the announcement means something simple but profound: more time, less disruption, and real hope where there once was little.